尽管内部人士的销售,但Thermo Fisher Scientific在2026年1月超过了利预期,提高了股息,并维持了股票回购. Thermo Fisher Scientific beat earnings estimates in January 2026, raised its dividend, and maintained share buybacks despite insider sales.

2026年1月, Thermo Fisher Science报称收入丰厚, 收入为6.57 EPS和122.2亿美元, 比上一年增加7.2%, In January 2026, Thermo Fisher Scientific reported strong earnings, with $6.57 EPS and $12.22 billion in revenue, up 7.2% year-over-year, beating estimates. 该公司将其季度红利提高了9.3%,达到每股0.47美元,并继续其股票回购方案。 The company raised its quarterly dividend by 9.3% to $0.47 per share and continued its share repurchase program. 机构所有权仍然很高,为89.23%,一些公司减少了股份,包括收割投资组合和Intech Investment Management等。 Institutional ownership remains high at 89.23%, while several firms reduced stakes, including Harvest Portfolios and Intech Investment Management. 人们注意到内部销售情况,包括高层主管的重要交易。 Insider sales were noted, including significant trades by top executives. 股价为633.68美元、市场上限为195.67亿美元、P/E比率为29.36。 The stock has a consensus "Moderate Buy" rating with a target price of $633.68, a market cap of $195.67 billion, and a P/E ratio of 29.36.